Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The selection of data sources for use in modelling studies.

M J Nuijten1

  • 1Lewin Group, Hoofddorp, The Netherlands. MNUYTEN@qbnt.quintiles.com

Pharmacoeconomics
|February 6, 1998
PubMed
Summary

This study addresses the critical need for robust methods in healthcare economic analysis, particularly for pharmaceutical evaluations. It provides a strategy for selecting appropriate secondary data sources and recommends transparent reporting formats for modeling studies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pharmacoeconomics in European decision-making.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2006
Same author

A cost-cost study comparing etanercept with infliximab in rheumatoid arthritis.

PharmacoEconomics·2001
Same author

Assessment of clinical guidelines for continuation treatment in major depression.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2001
Same author

Cost-effectiveness analysis of entacapone in Parkinson's disease: a Markov process analysis.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2001
Same author

Cost effectiveness of emedastine versus levocabastine in the treatment of allergic conjunctivitis in 7 European countries.

PharmacoEconomics·2001
Same author

Introduction to the pharmacoeconomics of herbal medicines.

PharmacoEconomics·2000

Area of Science:

  • Health Economics
  • Pharmaceutical Policy
  • Biostatistics

Background:

  • Economic analysis is crucial in healthcare, especially for pharmaceuticals.
  • Existing guidelines offer limited recommendations on using secondary data in economic modeling.
  • Methodological rigor in healthcare economic evaluations is essential.

Purpose of the Study:

  • To present a general strategy for determining the appropriateness of data sources in economic modeling.
  • To provide recommendations for transparent reporting of data source selection in pharmaceutical economic studies.

Main Methods:

  • Literature review of existing guidelines on secondary data use.
  • Development of a strategic framework for data source selection.
  • Formulation of reporting standards for data source transparency.

Related Experiment Videos

Main Results:

  • A systematic approach to evaluating secondary data suitability for economic models is proposed.
  • Specific recommendations for transparent reporting of data source selection are outlined.
  • The importance of data source justification in pharmaceutical economic evaluations is highlighted.

Conclusions:

  • Standardized methods for secondary data selection enhance the reliability of economic models.
  • Transparent reporting of data sources improves the credibility and reproducibility of pharmaceutical economic analyses.
  • Adoption of these recommendations will strengthen the evidence base for healthcare decision-making.